Efficacy and safety of fluticasone furoate 100 μg once-daily in patients with persistent asthma: a 24-week placebo and active-controlled randomised trial.

[1]  A. Woodcock,et al.  Once-daily fluticasone furoate alone or combined with vilanterol in persistent asthma , 2013, European Respiratory Journal.

[2]  R. Trivedi,et al.  Inhaled fluticasone furoate/vilanterol does not affect hypothalamic-pituitary-adrenal axis function in adolescent and adult asthma: randomised, double-blind, placebo-controlled study , 2013, The clinical respiratory journal.

[3]  A. Woodcock,et al.  Safety and tolerability of the novel inhaled corticosteroid fluticasone furoate in combination with the β2 agonist vilanterol administered once daily for 52 weeks in patients ≥12 years old with asthma: a randomised trial , 2013, Thorax.

[4]  A. Woodcock,et al.  Once-daily fluticasone furoate is efficacious in patients with symptomatic asthma on low-dose inhaled corticosteroids. , 2012, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[5]  A. Woodcock,et al.  Efficacy and safety of once-daily (OD) fluticasone furoate (FF) in patients with persistent asthma: A 24-week randomised trial , 2012 .

[6]  A. Woodcock,et al.  Efficacy of fluticasone furoate (FF) as a monotherapy and in combination with vilanterol (VI) over 12 weeks in patients with persistent asthma , 2012 .

[7]  C. Goldfrad,et al.  Combined fluticasone furoate/vilanterol reduces decline in lung function following inhaled allergen 23 h after dosing in adult asthma: a randomised, controlled trial , 2012, Clinical and Translational Allergy.

[8]  A. Woodcock,et al.  Dose effect of once-daily fluticasone furoate in persistent asthma: a randomized trial. , 2012, Respiratory medicine.

[9]  D. Klepser,et al.  Adherence and dosing frequency of common medications for cardiovascular patients. , 2012, The American journal of managed care.

[10]  A. Woodcock,et al.  Fluticasone furoate: once-daily evening treatment versus twice-daily treatment in moderate asthma , 2011, Respiratory research.

[11]  J. Flack,et al.  Benefits of once-daily therapies in the treatment of hypertension , 2011, Vascular health and risk management.

[12]  A. Woodcock,et al.  Efficacy in asthma of once-daily treatment with fluticasone furoate: a randomized, placebo-controlled trial , 2011, Respiratory research.

[13]  J. Haughney,et al.  Current Control and Future Risk in Asthma Management , 2011, Allergy, asthma & immunology research.

[14]  J. Bousquet,et al.  Adherence rate to beclomethasone dipropionate and the level of asthma control. , 2011, Respiratory medicine.

[15]  S. Spier,et al.  Adrenal suppression: A practical guide to the screening and management of this under-recognized complication of inhaled corticosteroid therapy , 2011, Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology.

[16]  A. Woodcock,et al.  Fluticasone furoate demonstrates efficacy in patients with asthma symptomatic on medium doses of inhaled corticosteroid therapy: an 8-week, randomised, placebo-controlled trial , 2011, Thorax.

[17]  H. Friedman,et al.  Treatment with inhaled mometasone furoate reduces short-acting β(2) agonist claims and increases adherence compared to fluticasone propionate in asthma patients. , 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[18]  H. Friedman,et al.  Adherence and asthma control with mometasone furoate versus fluticasone propionate in adolescents and young adults with mild asthma , 2010, The Journal of asthma : official journal of the Association for the Care of Asthma.

[19]  I. Adcock,et al.  Fluticasone Furoate, A Novel Enhanced-affinity Inhaled Corticosteroid (ICS), With Sustained Glucocorticoid Receptor Nuclear Translocation , 2010, ATS 2010.

[20]  J. L. Hermosa,et al.  Factors Associated With the Control of Severe Asthma , 2010, The Journal of asthma : official journal of the Association for the Care of Asthma.

[21]  G. Wennergren,et al.  West Sweden Asthma Study: Prevalence trends over the last 18 years argues no recent increase in asthma , 2009, Respiratory research.

[22]  Mark Kosinski,et al.  The minimally important difference of the Asthma Control Test. , 2009, The Journal of allergy and clinical immunology.

[23]  P. Jones,et al.  Fluticasone versus placebo for chronic asthma in adults and children. , 2008, The Cochrane database of systematic reviews.

[24]  I. McLay,et al.  X-ray crystal structure of the novel enhanced-affinity glucocorticoid agonist fluticasone furoate in the glucocorticoid receptor-ligand binding domain. , 2008, Journal of medicinal chemistry.

[25]  S. Farrow,et al.  Pharmacological properties of the enhanced-affinity glucocorticoid fluticasone furoate in vitro and in an in vivo model of respiratory inflammatory disease. , 2007, American journal of physiology. Lung cellular and molecular physiology.

[26]  N. Thomson,et al.  Efficacy of low and high dose inhaled corticosteroid in smokers versus non-smokers with mild asthma , 2005, Thorax.

[27]  R. Pauwels,et al.  Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. , 2004, American journal of respiratory and critical care medicine.

[28]  K. J. Macleod,et al.  Influence of cigarette smoking on inhaled corticosteroid treatment in mild asthma , 2002, Thorax.

[29]  B. Lipworth.  Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysis. , 1999, Archives of internal medicine.

[30]  S J London,et al.  A study of twelve Southern California communities with differing levels and types of air pollution. I. Prevalence of respiratory morbidity. , 1999, American journal of respiratory and critical care medicine.

[31]  W S Linn,et al.  A study of twelve Southern California communities with differing levels and types of air pollution. II. Effects on pulmonary function. , 1999, American journal of respiratory and critical care medicine.

[32]  Third Expert Panel on theDiagnosis,et al.  Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma , 1997 .

[33]  R. Pauwels,et al.  GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION , 1996 .

[34]  J. Hankinson,et al.  Performance of American Thoracic Society-recommended spirometry reference values in a multiethnic sample of adults: the multi-ethnic study of atherosclerosis (MESA) lung study. , 2010, Chest.

[35]  P. Barnes.  Inhaled Corticosteroids. , 2010, Pharmaceuticals.

[36]  G H Guyatt,et al.  Determining a minimal important change in a disease-specific Quality of Life Questionnaire. , 1994, Journal of clinical epidemiology.